MP
VYNE icon

Mangrove Partners’s VYNE Therapeutics VYNE Stock Holding History

Mangrove Partners’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-14,641
Closed -$2.83M – 65
2020
Q1 		$2.83M Buy
14,641
+5,209
+55% +$1.63M 0.39% 34
2019
Q4 		$3.15M Sell
9,432
-2,420
-20% -$807K 0.46% 32
2019
Q3 		$3.82M Hold
11,852
– – 0.46% 52
2019
Q2 		$5.11M Buy
11,852
+4,058
+52% +$2.01M 0.58% 36
2019
Q1 		$4.41M Buy
+7,794
New +$3.74M 0.59% 33

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mangrove Partners's VYNE Position: Q2 2020 in Review

Mangrove Partners sold out of VYNE Therapeutics (VYNE) in Q2 2020, closing a stake of 14,641 shares — an estimated $2.83M sold.

Mangrove Partners first reported a position in VYNE in Q1 2019 and held it in 5 quarters. The position peaked at $5.11M in Q2 2019. 106 funds tracked by Wall St. Rank hold VYNE as of Q2 2020.

  • Mangrove Partners reported no remaining VYNE Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Mangrove Partners sold 14,641 VYNE Therapeutics shares in Q2 2020, an estimated $2.83M.
  • Mangrove Partners first reported a position in VYNE Therapeutics in Q1 2019 and held it in 5 quarters.
  • Mangrove Partners's VYNE Therapeutics position peaked at $5.11M in Q2 2019.
  • 106 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2020.

Based on Mangrove Partners's 13F filing for Q2 2020, filed 14 Aug 2020.